Due to the lack of BCP-ALL engraftment of transformed CD79b-ITAM-KO cells, we hypothesized that blocking CD79b with a monoclonal antibody reduces BCP-ALL engraftment in vivo. Here, CD79B is linked to acute lymphoblastic leukemia.